A woman in her 80s with Alzheimer’s disease regained the ability to speak after consuming psilocybin, say researchers Lago et al. in a case report published in late May 2026.
At a glance, “psilocybin for Alzheimer’s” sounds too good to be true. Alzheimer’s disease afflicts roughly 11% of elderly people in the United States. Its effects are stark, unpredictable, and harrowing for both patients and their families. And psychedelic-assisted therapies may be an as-of-yet unturned relief valve. Here’s what we know so far about psilocybin for Alzheimer’s.
Before we dive into Lago’s findings on psilocybin for Alzheimer’s, let’s set the table. While intriguing, their work isn’t the first of its kind. In 2024, researchers Zheng & colleagues published a purported mechanism in Frontiers in Neuroscience.
Here’s the simple version:
That’s the link - on paper, anyway. Zheng writes of a lack of “robust experimental evidence” linking psilocin (the active version of the drug, converted in your body from psilocybin) to Alzheimer’s.
It’s possible that the two simply affect the same receptor without interacting with each other. To know for sure, we need more large-scale systematic reviews - which depend on a growing body of case report data.
Lago and colleagues describe a collection of truly startling effects. The subject of their case report, an octogenarian woman with 10 years of progressive Alzheimer’s disease, was given two doses of psilocybin as an “exploratory and observational” measure.
The subject had many of the hallmarks of Alzheimer’s, including “severe reductions” in spontaneous interaction, executive function, independent mobility, and codependence. Here’s what happened:
Most notably, the subject engaged in spontaneous conversation and demonstrated control over multisyllabic speech, whereas she had previously spoken very little in single syllables. Lago reports that, at one point and unprompted, the subject remarked, “It is pleasant to come here.”
Many of the observed changes remained positively elevated above baseline a month later.
One case report isn’t a tectonic shift; it’s another brick laid. This study points not to psilocybin as a so-called cure for Alzheimer’s, but, at minimum, it illuminates a potential relationship between the brain receptors most vulnerable to erosion and the neural effects of magic mushrooms.
Lago et al. put it this way: There may be “residual functional capacity” in late-stage Alzheimer’s patients which can be - temporarily at least - restored by psilocybin.
Other scientists have been plugging away at defining that clinical potential:
“Psychedelics can promote expression of neuronal growth factors, increase neuronal connections, and quell inflammation, all of which may have potential implications for the treatment of neurodegenerative diseases such as Alzheimer’s,” adds Dr. Sam Gandy, PhD in ecological sciences. It’s a sentiment echoed by Lago as well:
Psilocybin doesn’t cure Alzheimer’s. At minimum, it may help sufferers find temporary relief and regain much-needed autonomy. But for a disease which is so painfully, and incurably, debilitating, any relief is better than none.